BAKER BROS. ADVISORS LP Q2 2025 Filing
Filed August 14, 2025
Portfolio Value
$10.3B
Holdings
89
Report Date
Q2 2025
Filing Type
13F-HR
All Holdings (89 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ONCBeOne Medicines Ltd. | 8,799,053 | $2.1T | 20663.75% | |
| 2 | INCYIncyte Corporation | 30,743,275 | $2.1T | 20310.92% | |
| 3 | ACADACADIA Pharmaceuticals Inc. | 42,896,690 | $925.3B | 8976.48% | |
| 4 | IM8NInsmed Incorporated | 7,712,900 | $776.2B | 7530.45% | |
| 5 | SMMTSummit Therapeutics Inc. | 33,722,974 | $717.6B | 6961.93% | |
| 6 | MDGLMadrigal Pharmaceuticals, Inc. | 1,976,018 | $598.0B | 5801.62% | |
| 7 | RYTMRhythm Pharmaceuticals, Inc. | 5,604,483 | $354.1B | 3435.71% | |
| 8 | RVMDRevolution Medicines, Inc. | 9,364,972 | $344.5B | 3342.48% | |
| 9 | KYMRKymera Therapeutics, Inc. | 6,651,429 | $290.3B | 2816.00% | |
| 10 | ALKSAlkermes plc | 6,410,603 | $183.4B | 1779.30% | |
| 11 | REPLReplimune Group, Inc. | 11,045,336 | $102.6B | 995.47% | |
| 12 | RAREUltragenyx Pharmaceutical Inc. | 2,772,692 | $100.8B | 978.04% | |
| 13 | EWTXEdgewise Therapeutics, Inc. | 7,305,940 | $95.8B | 929.20% | |
| 14 | ABCLAbCellera Biologics Inc. | 27,525,640 | $94.4B | 915.93% | |
| 15 | IMVTImmunovant, Inc. | 5,457,881 | $87.3B | 847.18% | |
| 16 | GRALGRAIL, Inc. | 1,630,125 | $83.8B | 813.18% | |
| 17 | KNSAKiniksa Pharmaceuticals International, plc | 2,824,669 | $78.2B | 758.24% | |
| 18 | BCYCBicycle Therapeutics plc | 10,885,357 | $75.7B | 733.94% | |
| 19 | IMCRImmunocore Holdings plc | 2,322,656 | $72.9B | 707.08% | |
| 20 | CELCCelcuity Inc. | 5,450,445 | $72.8B | 705.90% | |
| 21 | KODKodiak Sciences Inc. | 17,310,490 | $64.6B | 626.40% | |
| 22 | IMTXImmatics N.V. | 10,168,901 | $54.7B | 530.75% | |
| 23 | STOKStoke Therapeutics, Inc. | 4,633,838 | $52.6B | 510.23% | |
| 24 | DNLIDenali Therapeutics Inc. | 3,731,695 | $52.2B | 506.47% | |
| 25 | GPCRStructure Therapeutics Inc. | 2,508,767 | $52.0B | 504.78% | |
| 26 | IDYAIDEAYA Biosciences, Inc. | 2,118,728 | $44.5B | 432.06% | |
| 27 | NRIXNurix Therapeutics, Inc. | 3,882,125 | $44.2B | 428.97% | |
| 28 | ROIVRoivant Sciences Ltd. | 3,767,773 | $42.5B | 411.95% | |
| 29 | BNTXBioNTech SE | 368,923 | $39.3B | 381.06% | |
| 30 | TRDAEntrada Therapeutics, Inc. | 4,865,819 | $32.7B | 317.22% | |
| 31 | MRUSMerus N.V. | 574,377 | $30.2B | 293.10% | |
| 32 | PRAXPraxis Precision Medicines, Inc. | 689,488 | $29.0B | 281.27% | |
| 33 | NTLAIntellia Therapeutics, Inc. | 2,675,674 | $25.1B | 243.48% | |
| 34 | VRDNViridian Therapeutics, Inc. | 1,744,406 | $24.4B | 236.58% | |
| 35 | GLUEMonte Rosa Therapeutics, Inc. | 4,916,095 | $22.2B | 215.09% | |
| 36 | VRNAVerona Pharma plc | 223,843 | $21.2B | 205.39% | |
| 37 | PCVXVaxcyte, Inc. | 640,885 | $20.8B | 202.13% | |
| 38 | ARGXargenx SE | 37,760 | $20.8B | 201.92% | |
| 39 | VERVVerve Therapeutics, Inc. | 1,691,530 | $19.0B | 184.29% | |
| 40 | CERSCerus Corporation | 12,883,844 | $18.2B | 176.24% | |
| 41 | IRONDisc Medicine, Inc. | 337,050 | $17.9B | 173.17% | |
| 42 | AKROAkero Therapeutics, Inc. | 324,630 | $17.3B | 168.05% | |
| 43 | 2L9Blueprint Medicines Corporation | 125,538 | $16.1B | 156.11% | |
| 44 | SERASera Prognostics, Inc. | 5,498,170 | $15.2B | 147.75% | |
| 45 | ARWRArrowhead Pharmaceuticals, Inc. | 939,174 | $14.8B | 143.96% | |
| 46 | NGNENeurogene Inc. | 991,691 | $14.8B | 143.83% | |
| 47 | DNTHDianthus Therapeutics, Inc. | 789,759 | $14.7B | 142.74% | |
| 48 | TCE2Celldex Therapeutics, Inc. | 665,370 | $13.5B | 131.36% | |
| 49 | DBVTDBV Technologies S.A. | 1,461,425 | $13.4B | 129.87% | |
| 50 | XENEXenon Pharmaceuticals Inc. | 370,208 | $11.6B | 112.41% | |
| 51 | CDTXCidara Therapeutics, Inc. | 227,272 | $11.1B | 107.40% | |
| 52 | ACLXArcellx, Inc. | 166,825 | $11.0B | 106.57% | |
| 53 | NUVLNuvalent, Inc. | 143,937 | $11.0B | 106.54% | |
| 54 | SYRESpyre Therapeutics, Inc. | 626,703 | $9.4B | 91.02% | |
| 55 | TSHATaysha Gene Therapies, Inc. | 4,004,756 | $9.3B | 89.75% | |
| 56 | PRLDPrelude Therapeutics Inc. | 10,123,824 | $8.2B | 79.50% | |
| 57 | CRNXCrinetics Pharmaceuticals, Inc. | 280,000 | $8.1B | 78.12% | |
| 58 | CTMXCytomX Therapeutics, Inc. | 3,484,226 | $7.9B | 76.73% | |
| 59 | SGMTSagimet Biosciences Inc. | 952,996 | $7.3B | 70.45% | |
| 60 | SIONSionna Therapeutics, Inc. | 400,000 | $6.9B | 67.33% | |
| 61 | AGIOAgios Pharmaceuticals, Inc. | 189,866 | $6.3B | 61.26% | |
| 62 | RAPPRapport Therapeutics, Inc. | 550,090 | $6.3B | 60.68% | |
| 63 | SKYESkye Bioscience, Inc. | 1,450,638 | $6.1B | 58.83% | |
| 64 | DSGNDesign Therapeutics, Inc. | 1,712,882 | $5.8B | 56.00% | |
| 65 | KALAKALA BIO, Inc. | 1,201,894 | $5.7B | 55.50% | |
| 66 | SANASana Biotechnology, Inc. | 2,030,949 | $5.5B | 53.79% | |
| 67 | XNCRXencor, Inc. | 670,431 | $5.3B | 51.12% | |
| 68 | ALMSAlumis Inc. | 1,562,500 | $4.7B | 45.48% | |
| 69 | 1K0IGM Biosciences, Inc. | 4,096,210 | $4.6B | 44.51% | |
| 70 | TCRXTScan Therapeutics, Inc. | 2,784,792 | $4.0B | 39.17% | |
| 71 | RLAYRelay Therapeutics, Inc. | 1,160,117 | $4.0B | 38.94% | |
| 72 | FATEFate Therapeutics, Inc. | 2,485,018 | $2.8B | 27.00% | |
| 73 | VIRVir Biotechnology, Inc. | 542,539 | $2.7B | 26.53% | |
| 74 | ELVNEnliven Therapeutics, Inc. | 114,833 | $2.3B | 22.35% | |
| 75 | WVEWave Life Sciences Ltd. | 344,063 | $2.2B | 21.70% | |
| 76 | TECXTectonic Therapeutic, Inc. | 100,000 | $2.0B | 19.28% | |
| 77 | CADLCandel Therapeutics, Inc. | 355,112 | $1.8B | 17.43% | |
| 78 | TARAProtara Therapeutics, Inc. | 536,832 | $1.6B | 15.78% | |
| 79 | VTVTvTv Therapeutics, Inc. | 97,314 | $1.5B | 14.16% | |
| 80 | RCKTRocket Pharmaceuticals, Inc. | 552,079 | $1.4B | 13.12% | |
| 81 | CTNMContineum Therapeutics, Inc. | 312,500 | $1.2B | 12.04% | |
| 82 | HOOKHOOKIPA Pharma Inc. | 812,814 | $1.0B | 9.90% | |
| 83 | NMRANeumora Therapeutics, Inc. | 1,034,600 | $758.7M | 7.36% | |
| 84 | GBIOGBXGeneration Bio Co. | 1,944,945 | $622.6M | 6.04% | |
| 85 | ALGSAligos Therapeutics, Inc. | 83,055 | $598.8M | 5.81% | |
| 86 | TYRATyra Biosciences, Inc. | 10,607 | $101.5M | 0.98% | |
| 87 | ACRVAcrivon Therapeutics, Inc. | 22,809 | $27.1M | 0.26% | |
| 88 | SRZNWSurrozen, Inc. | 833,333 | $15.1M | 0.15% | |
| 89 | OPTEYOpthea Limited | 2,087,320 | $0 | 0.00% |